1-Alkylpyrazoles and 1-alkyl-5-chloropyrazoles from halovinyl ketones and 1,1-dialkylhydrazines
摘要:
Regioselective heterocyclization of alkyl 2-chloro- and 2,2-dichlorovinyl ketones with 1,1-dialkylhydrazines to 1,3-dialkyl-1H-pyrazoles and 1,3-dialkyl-5-chloro-1H-pyrizoles involves intermediate formation of the corresponding dialkylhydrazones. Fragmentation pattern of chlorine-containing pyrazoles, 3-chloromethyl-1-methyl-1H-pyrazole and 5-chloro-1-methyl-3-propyl-1H-pyrazole, depends on the position of the halogen atom.
NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
申请人:FUJIFILM Corporation
公开号:US20150322063A1
公开(公告)日:2015-11-12
A compound represented by Formula [1] (in the formula, Z
1
represents N, CH, or the like; X
1
represents NH or the like; R
1
represents a heteroaryl group or the like; each of R
2
, R
3
, and R
4
represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R
5
represents a heteroaryl group or the like) or salt thereof.
[EN] PIKFYVE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE PIKFYVE
申请人:ACURASTEM INCORPORATED
公开号:WO2021163727A1
公开(公告)日:2021-08-19
The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
Disclosed herein are substituted phosphodiesterase type 5 enzyme modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
披露的是式I的取代的磷酸二酯酶5型酶调节剂,其制备过程,药物组合物及其用途。
[EN] 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINE 2,3,5-TRISUBSTITUÉS
申请人:ARCUS BIOSCIENCES INC
公开号:WO2020247496A1
公开(公告)日:2020-12-10
Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.
The present invention relates to compounds of Formula (I)
and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.